NCT01943513已完成1 期
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Intravenous BIIB023 (Anti-TWEAK) on Lower Limb Muscle Mass and Strength During and After Knee-Joint Immobilization in Healthy Male Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Percentage change in the magnitude of muscle atrophy
研究概览
简要总结
The primary objective of this study is to determine whether muscle atrophy induced by immobilization of the lower limb can be attenuated by BIIB023 in healthy male volunteers. The secondary objectives of this study in this study population are:
- To determine whether muscle weakness induced by immobilization of the lower limb can be attenuated by BIIB023
- To assess the effect of BIIB023 on the recovery of muscle mass and strength after immobilization
- To assess the effect of BIIB023 on histological markers of muscle atrophy and regeneration
- To assess the effect of BIIB023 on muscle bioenergetics based on oxidative metabolism recovery kinetics
- To evaluate the safety and tolerability of BIIB023
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Deemed healthy as determined by the Investigator based on medical history, 12-lead electrocardiogram, vital signs, and clinical laboratory parameters at Screening, and physical examination at Baseline
- •Body mass index (BMI) between 18.5 and 32 kg/m2, inclusive, at the time of Screening
- •Willing to abstain from using tobacco and tobacco-containing products during the study
- •Willing to limit the intake of alcohol to no more than 2 units per day throughout the study; exceptions are 48 hours prior to Screening, 48 hours prior to Day 1, and during the in-clinic immobilization period when no alcohol will be permitted. One unit of alcohol is defined as 12 fluid ounce (fl oz) of beer, 5 fl oz of wine, or 1.5 fl oz of liquor
- •Willing to maintain a regular diet for the duration of the study and a recreational level of physical activity defined as participation in an exercise program or other physical activity at a level of intensity that does not exceed the level prior to study entry
- •Practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after the last dose of study treatment.
排除标准
- •History of or positive test result at Screening for human immunodeficiency virus (HIV).
- •History or positive test result at Screening for hepatitis C virus (HCV) antibody or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
- •History of tuberculosis (TB) or a positive QuantiFERON®-TB Gold test. There must be no other clinical evidence of TB on physical examination of the subject.
- •Use of tobacco or tobacco-containing products within 3 months prior to Screening
- •Known history of thrombophilia, hypercoagulopathy, or prior history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
- •History of physical activity consistent with endurance training or resistance training within 6 months prior to Screening
- •Any back, leg, knee, or shoulder complaints that may interfere with the use of crutches
- •Prolonged travel (more than 6 hours) within 2 weeks prior to randomization.
- •NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Percentage change in the magnitude of muscle atrophy
时间窗: between Day 14 and Day 42
次要结局
- Change in density of satellite cells and other molecular markers of muscle regeneration, measured by histological analysis of muscle biopsy(between Day 14, Day 21, and Day 42)
- Percentage change in isometric knee-extension strength (torque), measured by dynamometry(between Day 14 and Day 42)
- Percentage change in isometric plantar-flexion strength (torque), measured by dynamometry(between Day 14 and Day 42)
- Percentage change in total CSA of Type I and II fibers, measured by histological analysis of muscle biopsy(between Day 14, Day 21, and Day 42)
- Percentage change in the magnitude of muscle atrophy, measured by T1W-MRI analysis of the CSA of the triceps surae muscles of the immobilized limb(between Day 14 and Day 42)
- The number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)(Day 156)
- Change in the recovery of muscle oxidative metabolism, measured by near-infrared spectroscopy (NIRS) of the quadriceps femoris muscles(between Day 14 and Day 42)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy VolunteerHealthy VolunteersNCT04708847Chugai Pharmaceutical30
已完成
1 期
Preventive Effect of Proprioceptive Stimulation on Muscle AtrophyKnee ArthritisNCT01641627University Hospital, Lille34
已完成
2 期
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial DiseaseIntermittent ClaudicationNCT00443287Sanofi553
已完成
1 期
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCISpinal Cord InjuriesSpine DiseaseStrokeNCT05589402University of Texas Rio Grande Valley52
已完成
3 期
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor NeuropathyMultifocal Motor NeuropathyNCT00666263Baxalta now part of Shire50